Top > Search of International Patents > AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA

AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA

Foreign code F130007122
File No. S2011-0895-N0
Posted date Jan 23, 2013
Country WIPO
International application number 2012JP066207
International publication number WO 2013005603
Date of international filing Jun 26, 2012
Date of international publication Jan 10, 2013
Priority data
  • P2011-147038 (Jul 1, 2011) JP
Title AGENT FOR PREVENTION AND/OR TREATMENT OF ALLERGIC INFLAMMATION IN CONJUNCTIVA
Abstract Provided are eye drops, and a subconjunctival injection drug for refractory allergic conjunctival disease, foremost for seasonal allergic conjunctivitis. This agent for prevention and/or treatment of allergic inflammation in the conjunctiva contains semaphorin-3A as an active component.
Outline of related art and contending technology BACKGROUND ART
In recent years, typified by hay fever has increased over the allergic diseases, involving multiple organs, occupies about 30% of the population, a great social problem. Pollen allergic conjunctival disease patient is estimated to be about 85% and property, there is a severe cases a proportion of at least 1% (non-patent document 1). As causing an increase in these allergic diseases, air pollutants and to be associated with pointed out.
Current, anti-allergic eye drops is formulated and type 9, anti-histamine eye drops is mostly used. However, non-steroidal ophthalmic drug effect is not enough. Allergic reaction type I allergic conjunctival disease is a collective term for disease involving the conjunctiva, a variety of lesion only anti-allergic eye drops cannot be suppressed, has been formulated steroid eye drops (non-patent document 2).
On the other hand, steroid eye drops is, of the effect is large, local eye increased intraocular pressure, cataract, retinopathy, the induction of infection progression, vascular abnormalities, skin conditions, there is a strong side effects such as hirsutism, cannot be easily continued. Therefore, as a therapeutic agent is administered to the non-steroidal instead, conjunctiva steroid drug more angular peripheral nerve paraesthesia, avoid side effects such as conjunctival vascular abnormalities, strong effect are eye drops has been developed.
The functions of the immune system revealed typical semaphorin molecule is Sema3A, the functions of the nervous system in the world as guidance factor has been industriously analysis (non-patent document 3) is, immune cell migration inhibitory effects have also been reported in recent years (non-patent document 4). T cell receptor (TCR) signaling pathway or inhibition of MAP kinase signaling pathway, or actin integrated inhibition than suppressing the activation of, in addition, complex pelexin-A4 NP-1/Sema3A as receptors for the negative T cell immune response was reported to be involved in the control (non-patent document 5 and 6).
However, allergic conjunctival disease semaphorin molecule Sema3A report to the effect that is not effective.
Scope of claims (In Japanese)請求の範囲 [請求項1]
セマフォリン3Aを有効成分として含有する、結膜におけるアレルギー性炎症の予防及び/又は治療剤。

[請求項2]
結膜におけるアレルギー性炎症が季節性アレルギー結膜炎である請求項1記載の予防及び/又は治療剤。

[請求項3]
季節性アレルギー性結膜炎が花粉症である請求項2記載の予防及び/又は治療剤。

[請求項4]
セマフォリン3Aの医薬的に有効な量を被験者に投与することを含む、結膜におけるアレルギー性炎症を予防及び/又は治療する方法。

[請求項5]
結膜におけるアレルギー性炎症の予防及び/又は治療のためのセマフォリン3Aの使用。

[請求項6]
結膜におけるアレルギー性炎症を予防及び/又は治療する方法に使用するためのセマフォリン3A。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • Public University Corporation Yokohama City University
  • Inventor
  • TANAKA, Junmi
  • MIZUKI, Nobuhisa
  • GOSHIMA, Yoshio
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close